Physician profile
Anju Singhal
NPI 1861636755
$12,700.48
in general payments reported to CMS, 2019-2025
38 companies · $7,929 in 2025
The $7,929 reported for 2025 was more than what 94% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $143 · 2021: $738 · 2022: $1,007 · 2023: $937 · 2024: $1,946 · 2025: $7,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,979 · Consulting Fee: $4,880 · Travel and Lodging: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,979.20 |
| Consulting Fee | $4,880.00 |
| Travel and Lodging | $953.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $6,223.42 | 2022-2025 | Trikafta |
| United Therapeutics Corporation | $1,517.34 | 2020-2025 | Orenitram, Remodulin, Remodulin |
| Actelion Pharmaceuticals US, INC. | $543.24 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Bayer Healthcare Pharmaceuticals INC. | $455.94 | 2020-2025 | |
| Insmed, INC. | $446.82 | 2021-2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.00 | 2023-2025 | Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $278.65 | 2022-2025 | Livtencity |
| Mylan Specialty L.P. | $278.26 | 2023-2024 | Tobi Podhaler, Yupelri |
| Paratek Pharmaceuticals, INC. | $265.15 | 2024-2025 | Nuzyra |
| Abbvie INC. | $218.66 | 2023-2025 | Avycaz, Teflaro |
| Electromed, INC. | $216.64 | 2022-2025 | Smartvest |
| Merck Sharp & Dohme LLC | $161.04 | 2022-2025 | Winrevair |
| Astellas Pharma US INC | $156.34 | 2020-2025 | Cresemba |
| Davol INC. | $149.83 | 2022 | |
| Ani Pharmaceuticals, INC. | $145.15 | 2024-2025 | Purified Cortrophin Gel |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $136.71 | 2021 | |
| Gilead Sciences, INC. | $132.46 | 2021-2024 | Epclusa |
| Vifor Pharma, INC. | $129.87 | 2024-2025 | Zemaira |
| Viatris Specialty LLC | $128.24 | 2025 | Tobi Podhaler |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2021 | |
| Glaxosmithkline, LLC. | $124.21 | 2025 | Nucala |
| Kamada LTD. | $110.31 | 2025 | |
| Melinta Therapeutics, LLC | $72.80 | 2024-2025 | Rezzayo, Vabomere |
| Sandoz INC. | $55.59 | 2021-2022 | |
| Shionogi INC | $45.34 | 2021-2022 | |
| La Jolla Pharmaceutical Company | $41.21 | 2023-2024 | Giapreza |
| Genentech USA, INC. | $33.00 | 2021-2022 | |
| Alcresta Therapeutics, INC. | $29.44 | 2022 | |
| Mallinckrodt Hospital Products INC. | $25.23 | 2023 | Acthar |
| Baxter Healthcare | $19.24 | 2025 | Hillrom - Monarch Airway Clearance System |
| Vivus LLC | $18.80 | 2023 | Pancreaze |
| Advanced Respiratory, INC | $18.34 | 2021 | |
| Cmp Pharma, INC. | $17.25 | 2022 | |
| Invivyd INC | $16.66 | 2025 | Pemgarda |
| Aimmune Therapeutics, INC. | $16.01 | 2025 | Zenpep |
| Eurofins Viracor, LLC | $15.99 | 2025 | |
| Philips North America LLC | $15.30 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anju Singhal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.